Sohrab P. Shah

Memorial Sloan Kettering Cancer Center

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index90

i10-index163

Publications614

Citations44,645

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 161

Figure S1 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Figure S4 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Figure S2 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Figure S5 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Figure S3 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Intracranial pharmacokinetics and resistance mechanisms of tucatinib in patients with HER2+/mutant solid tumors and brain metastasis: Results from the WinHER2 study (NCT05892068).
Journal of Clinical Oncology · 2026-05-27
Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology
Nature Communications · 2025-11-27 · 2 citations
Supplementary Figure S5 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Figure S8 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Figure S2 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Figure S3 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Figure S6 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Table S3 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Figure S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Table S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Table S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Figure S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Table S4 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25
Supplementary Figure S9 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
2025-11-25

Open author page on OpenAlex →